Skip to main content

Find Alzheimer’s Disease and Related Clinical Trials

Search for clinical trials and studies related to Alzheimer's, other dementias, mild cognitive impairment, and caregiving.

Clinical Trials Search Results

Results found: 57

ACI-24 Vaccine in Adults with Down Syndrome

Purpose: To test the ACI-24 vaccine in adults with Down syndrome.

This Phase I Study Will Test The ACI-24 Vaccine In Adults With Down Syndrome To Assess Whether The Vaccine Is Safe, Tolerable, And Able To Stimulate An Immune Response.

AD-35 for Mild to Moderate Alzheimer's

Purpose: To evaluate the safety, tolerability, efficacy, and behavior of AD-35 in older adults with mild to moderate Alzheimer's disease.

This Phase II Trial Will Test The Safety, Tolerability, And Effects Of AD-35 On Cognitive Function In Older Adults With Mild To Moderate Alzheimer's Disease.

AGB101 for Mild Cognitive Impairment Due to Alzheimer's Disease

Purpose: To evaluate the efficacy of AGB101 in slowing cognitive and functional impairment in people with mild cognitive impairment (MCI) due to Alzheimer's.

This Phase III Clinical Trial Will Evaluate Whether AGB101 Slows Cognitive And Functional Impairment In People With Prodromal Alzheimer's Disease (mild Cognitive Impairment Due To Alzheimer's)

AL001 for Frontotemporal Dementia in Healthy Volunteers and People with FTD

Purpose: To assess the safety, tolerability, and behavior of the drug AL001 in healthy adult volunteers and people with frontotemporal dementia and the granulin mutation.

This Phase 1 Study Is Testing The Investigational Drug AL001 As A Possible Treatment For Frontotemporal Dementia (FTD) In Healthy Volunteers And People With FTD Who Also Have A Granulin Mutation (PGRN).

AMX0035 to Treat Alzheimer's Disease

Purpose: To assess the safety, tolerability, and effects of the investigational drug AMX0035 for people with late mild cognitive impairment or early dementia due to Alzheimer's disease.

This Phase II Study Will Assess The Safety, Tolerability, And Effects Of The Investigational Drug AMX0035 For People With Late Mild Cognitive Impairment Or Early Dementia Due To Alzheimer's Disease.

AR1001 for Mild to Moderate Alzheimer's Disease

Purpose: To evaluate the efficacy and safety of AR1001 in people with mild to moderate Alzheimer's disease.

This Phase II Trial Will Investigate The Efficacy And Safety Of The Investigational Drug AR1001 In Older Adults With Mild To Moderate Alzheimer's Disease For 26 Weeks.

AVP-786 for the Treatment of Agitation in Alzheimer's

Purpose:To evaluate AVP-786, compared to placebo, for the treatment of agitation in people with Alzheimer's-type dementia.

This Phase III Clinical Trial Will Evaluate The Efficacy, Safety, And Tolerability Of The Drug AVP-786 As A Treatment For Agitation In People With Alzheimer's Disease.

AXS-05 for Agitation in Alzheimer's

Purpose: To assess the efficacy and safety of investigational drug AXS-05 in treating agitation in older adults with Alzheimer's.

This Phase II/III Randomized Trial Will Assess The Efficacy And Safety Of AXS-05, An Investigational Drug Combining FDA-approved Bupropion And Dextromethorphan, To Treat agitation In Older Adults With Alzheimer's Disease.

Antidepressants to Prevent Mild Cognitive Impairment

Purpose: To test two antidepressants in people with subjective cognitive impairment.

This Study Will Test Two Antidepressants, Escitalopram (Lexapro) And Venlafaxine (Effexor XR), To Assess Their Effects On Memory And Cognition In People With Subjective Cognitive Impairment. Participants Are Cognitively Normal But Are Concerned About Their memory.

Apathy in Dementia Methylphenidate Trial 2 (ADMET 2)

Purpose: To test methylphenidate (Ritalin®) as a treatment for clinically significant apathy in people with Alzheimer's disease.

ADMET 2 Will Test Methylphenidate (Ritalin), A Drug Approved To Treat Symptoms Of Attention Deficit Hyperactivity Disorder And Narcolepsy, As Treatment For Clinically Significant Apathy In People With Alzheimer's Disease.

Assessing J147 for Alzheimer's in Healthy Volunteers

Purpose: To assess the safety, tolerability, and pharmacokinetics of the investigational drug J147 in healthy young and older adults.

This Phase I Clinical Study Will Assess The Safety And Pharmacokinetics Of The Experimental Drug J147 In Healthy Adults. Researchers Are Investigating the Drug As A Potential Treatment For Alzheimer's Disease.

BAN2401 for People with Early Alzheimer's Disease

Purpose: To test the experimental drug BAN2401 in people with early Alzheimer's disease

This Phase III Trial Will Test The Effectiveness Of The Experimental Drug BAN2401 As A Possible Treatment For Alzheimer's Disease. 

BHV-4157 for Alzheimer's Disease (T2 Protect AD)

Purpose: To test the investigational drug BHV-4157 as a possible treatment and prevention for the symptoms of Alzheimer's disease.

BHV-4157, Also Known As Troriluzole, Is An Investigational Drug That Researchers Are Testing To Determine If It Can Protect Against, Slow Down, And Potentially Improve Memory And Thinking Problems In Adults With Mild To Moderate Alzheimer's Disease.

BIIB076 for Early Alzheimer's Disease

Purpose: To evaluate the safety and tolerability of BIIB076 in cognitively normal older adults and older adults with Alzheimer's disease.

This Study Will Evaluate The Safety And Tolerability Of BIIB076 In Cognitively Normal Older Adults And Older Adults With Alzheimer's Disease.

BIIB092 in Primary Tauopathies

Purpose: To test the safety, tolerability, and effects of the investigational drug BIIB092 in people with one of four different tauopathy syndromes.

This Phase 1b Randomized Clinical Trial Will Test The Safety, Tolerability, And Effects Of The Investigational Drug BIIB092, A Monoclonal Antibody, When It Is Intravenously Infused In People That Have One Of Four Different Tauopathy Syndromes.

BPN14770 for Early Alzheimer's (PICASSO)

Purpose: To evaluate the effects of BPN14770 in older adults with early-stage Alzheimer's disease.

This Phase II Trial Will Test The Effects Of Different Doses Of The Experimental Drug BPN14770 In People With Early-stage Alzheimer's Disease. BPN14770 Is Being Investigated For Its Potential To Treat Memory Loss And Improve Cognitive Function.

Blood Pressure Control to Reduce Amyloid-Beta Accumulation (HIPAC)

Purpose: To determine if lowering blood pressure using antihypertensive drugs alters brain pulsatility, a measure of blood flow, and reduces beta-amyloid accumulation in the brains of cognitively normal older adults.

This Phase II Study Will Test Whether Lowering Blood Pressure Using Antihypertensive Drugs Alters Brain Pulsatility, A Measure Of Blood Flow, And Reduces Amyloid-beta Accumulation In The Brains Of Older Adults.

Bosutinib for the Treatment of Dementia with Lewy Bodies

Purpose: To evaluate the drug bosutinib as a treatment for people with dementia with Lewy bodies.

This Phase II Study Will Evaluate the Cancer Drug Bosutinib (Bosulif) As A Possible Treatment For People With Mild To Moderate Dementia With Lewy Bodies.

Brexpiprazole for Agitation in Alzheimer's

Purpose: To compare the efficacy of two doses of brexpiprazole (Rexulti) in older adults with agitation associated with Alzheimer's disease.

This Phase III Study Compares The Efficacy Of Two Different Doses Of Brexpiprazole (Rexulti) With Placebo In Older Adults Who Are Experiencing Agitation Associated With Alzheimer's Disease.

CT1812 and Brain Synaptic Density in Mild to Moderate Alzheimer's

Purpose: To test the effect of the investigational drug CT1812 on brain synaptic density in adults with mild to moderate Alzheimer's disease.

This Phase I/II Study Will Test The Effects Of The Investigational Drug CT1812 On Brain Synaptic Density In Adults With Mild To Moderate Alzheimer's Disease.

CT1812 for Mild to Moderate Alzheimer's Disease

Purpose: To study the safety and efficacy of CT1812 in older adults with mild to moderate Alzheimer's disease.

This Phase II Trial Will Study The Safety And Efficacy Of Two Different Doses Of The Investigational Drug CT1812 In Adults With Mild To Moderate Alzheimer's Disease.

Candesartan's Effects on Alzheimer's Disease and Related Biomarkers

Purpose: To investigate the effect of candesartan, a blood pressure medication, on cognitive function in people with mild cognitive impairment.

This Phase II Study Will Investigate The Effect Of Candesartan, A Medication Used To Treat High Blood Pressure, On Cognitive Function In People With Mild Cognitive Impairment (MCI), A Condition Of Higher-than-normal Memory And Thinking Difficulties For One's Age.

Cholinesterase Inhibitor Discontinuation

Purpose: To determine if stopping certain medications for Alzheimer's disease will cause worsened cognition, functioning, or behavior in veterans with advanced dementia.

This Study Aims To Determine If Stopping Certain Medications For Alzheimer's Disease Will Cause Worsened Cognition, Functioning, Or Behavior In Veterans With Advanced Dementia Who Have Been Taking A CI (donepezil Or Galantamine) For At Least One Year.

Dapagliflozin in Alzheimer's Disease

Purpose: To test the effects of the drug dapagliflozin in adults with mild to moderate Alzheimer's disease.

This Study Will Test The Effects, Safety, And Tolerability Of Dapagliflozin, Also Known As Farxiga, In Adults With Mild To Moderate Alzheimer's Disease. Researchers Are Investigating Whether This Drug Can Slow Alzheimer's Disease.

Down Syndrome Memantine Follow-up Study

Purpose: To determine if the drug memantine can improve learning and memory in adolescents and young adults with Down syndrome.

This Study Will Determine If The Alzheimer's Disease Drug Memantine Hydrochloride Can Improve Learning And Memory In Adolescents And Young Adults With Down Syndrome.

Dronabinol to Treat Agitation in Alzheimer's Disease

Purpose: To test the safety and efficacy of dronabinol to treat agitation in older adults with Alzheimer's.

This Trial Will Test The Safety And Efficacy Of Dronabinol (Marinol), A Medication Approved To Treat Chemotherapy-related Nausea And Vomiting And AIDS-related Lack Of Appetite, In Treating Agitation In Older Adults With Alzheimer's.

E2609 for MCI and Early Alzheimer's (Mission AD1)

Purpose: To evaluate the efficacy and safety of E2609, or elenbecestat, in older adults with mild cognitive impairment and mild Alzheimer's disease.

This Phase III study Is Testing The Efficacy And Safety Of The Experimental Drug E2609, Or Elenbecestat, for The Treatment Of Early Alzheimer's Disease In Older Adults With Mild Cognitive Impairment (MCI) Or Mild Alzheimer's Disease.

E2609 for MCI and Early Alzheimer's (Mission AD2)

Purpose: To evaluate the efficacy and safety of E2609, or elenbecestat, in older adults with mild cognitive impairment and mild Alzheimer's disease.

This Phase III study Is Testing The Efficacy And Safety Of The Experimental Drug E2609, Or Elenbecestat, For The Treatment Of Early Alzheimer's Disease In Older Adults With Mild Cognitive Impairment (MCI) Or Mild Alzheimer's Disease.

Escitalopram for Agitation in Alzheimer's Disease

Purpose: To evaluate the safety and efficacy of escitalopram (Lexapro) to treat agitation in Alzheimer's disease.

This Study Will Evaluate The Safety And Efficacy Of Escitalopram (Lexapro) To Treat Agitation In Alzheimer's Disease.

Exercise and Vascular Risk Reduction for Alzheimer's

Purpose: To test the effects of exercise and vascular risk reduction on cognitive performance in older adults at high risk for Alzheimer's.

Physical Inactivity, High Blood Pressure, And High Cholesterol Levels Are Risk Factors For Alzheimer's Disease And Vascular Dementia; However, These Risk Factors Are Modifiable With Lifestyle Changes And Medications. This Study Will Test The Effects Of Aerobic Exercise And Vascular Risk Reduction On Cognitive Performance In Older Adults Who Are At Risk For Alzheimer's Disease.

GAIN Trial: COR388 for Alzheimer's Disease

Purpose: To test the efficacy, safety, and tolerability of two doses of the investigational drug COR388 in older adults with mild to moderate Alzheimer's disease.

This Phase II/III clinical Trial Will Test The Efficacy, Safety, And Tolerability Of COR388 In Older Adults With Mild To Moderate Alzheimer's Disease. Researchers Are Investigating The Drug As A Potential Treatment For The Disease.

GRF6019 Infusions for Severe Alzheimer's Disease

Purpose: To evaluate the safety, tolerability, and potential cognitive benefit of the experimental treatment GRF6019 in older adults with severe Alzheimer's disease.

This Phase II Study Will Evaluate The Safety, Tolerability, And Potential Cognitive Benefit Of An Intraveneous Infusion Of GRF6019, A Plasma-derived Product, To Treat Older Adults With Severe Alzheimer's Disease.

Gantenerumab for Early Alzheimer's Disease

Purpose: To evaluate the efficacy and safety of the investigational drug gantenerumab in people with early Alzheimer's disease.

This Phase III Clinical Trial Will Evaluate The Efficacy And Safety Of Gantenerumab In People with Early-stage Alzheimer's Disease. Gantenerumab is An Experimental Medication That Is Being Investigated For Its Ability To Reduce Beta-amyloid Plaques In The Brain That Are associated With Alzheimer's Disease. This Trial Is Similar To Safety And Efficacy Of Gantenerumab For Early Alzheimer's, But Recruiting In Different Locations.

Insulin Aspart to Fight Forgetfulness

Purpose: To test the effects of fast-acting intranasal insulin on cognition and daily function in people with Alzheimer's disease or mild cognitive impairment.

This Phase I Clinical Trial Will Test The Effects Of Fast-acting Intranasal Insulin On Cognition And Daily Function In People With Alzheimer's Disease Or Mild Cognitive Impairment. Researchers Will Also Examine Markers Of Alzheimer's In Blood And Cerebrospinal Fluid And Amyloid Deposition In The Brain.

LY3154207 for Parkinson's Disease Dementia (PRESENCE)

Purpose: To evaluate the safety and efficacy of the investigational drug LY3154207 in people with mild-to-moderate Parkinson's disease dementia.

This Trial Will Test Multiple Doses Of The Investigational Drug LY3154207 In People With Mild-to-moderate Parkinson's Disease Dementia.

LY3303560 for Early Symptomatic Alzheimer's Disease

Purpose: To evaluate the safety and efficacy of experimental drug LY3303560 in people with early-stage Alzheimer's disease.

This Study Will Evaluate The Safety And Efficacy The Experimental Drug LY3303560 In People With Early-stage Alzheimer's Disease. 

Levetiracetam for Alzheimer's Disease-Associated Epileptiform Activity

Purpose: To test the use of levetiracetam, an anticonsulvant, to control seizures in people with Alzheimer's disease.

This Study Will Test The Use Of Levetiracetam (Keppra), An Approved Treatment For Epilepsy, To Control Seizures In People With Alzheimer's Disease. Many People With Alzheimer's Have Seizures And Other Overactive Electrical Activity In The Brain That Is Not Noticeable But May Contribute To The Loss Of Cognitive Function. 

Memory Improvement Through Nicotine Dosing (MIND)

Purpose: To test the effects of a nicotine skin pitch on memory performance in older adults with mild cognitive impairment (MCI).

Nicotine Has Been Shown To Improve Attention, Learning, And Memory. Researchers In This Phase II Trial Will Test Whether Nicotine Delivered Via A Transdermal (skin) Patch May Improve Memory Performance In Older Adults Who Are Experiencing Mild Cognitive Impairment (MCI).

NDX-1017 in Healthy Volunteers and People with Mild Alzheimer's

Purpose: To evaluate the safety, tolerability, and action of the experimental drug NDX-1017 in healthy volunteers and adults with mild Alzheimer's disease.

This Phase 1 Trial Will Test An Experimental Drug, NDX-1017, in Healthy Adults And People With Mild Alzheimer's Disease To Evaluate Safety, Dosing, And Action Of The Drug.

Nighttime Agitation and Restless Legs Syndrome in Nursing Home Residents with Alzheimer's

Purpose:To test whether Horizant, a drug approved for treating restless legs syndrome (RLS), could reduce nighttime agitation and improve sleep in nursing home residents with Alzheimer's and RLS.

Nighttime Agitation Causes Distress For People With Alzheimer's And Their Caregivers. Previous Research Has Identified A Possible connection Between Restless Legs Syndrome (RLS) And Nighttime Agitation And Sleep Disturbance In People With Alzheimer's. In This Study, Researchers Will Explore Whether RLS May Be A Cause Of Nighttime Agitation And if An Approved Treatment For RLS, Horizant (gabapentin Enacarbil), Reduces Or Stops Agitation And Improves Sleep. 

Nilotinib for Dementia with Lewy Bodies

Purpose: To evaluate the effects of nilotinib in adults with dementia with Lewy bodies.

This Phase II Trial Will Test The Effects Of The Drug Nilotinib (Tasigna) In Adults With Dementia With Lewy Bodies. Nilotinib Is Being Investigated As A Potential Treatment For The Neurodegenerative Disease.

Pimavanserin for Relapse of Dementia-Related Psychosis

Purpose: To evaluate the efficacy of the drug pimavanserin (Nuplazid) in preventing a relapse of psychotic symptoms in adults with who were previously stabilized after 12 weeks of treatment.

This Phase III Study Will Test The Drug Pimavanserin (Nuplazid) for Preventing A Relapse Of Psychotic Symptoms, Such As Hallucinations And Delusions, In Adults With Dementia Who Were Previously Stabilized After 12 Weeks Of Treatment.

Posiphen in Early Alzheimer's Disease (Discover Study)

Purpose: To evaluate Posiphen® in older adults with early-stage Alzheimer’s disease.

This Phase I Trial Will Evaluate The Safety, Pharmacokinetics, And Efficacy of Three Different Doses Of The Experimental Drug Posiphen In Older Adults With Early-stage Alzheimer's Disease.

Prazosin in Veterans with Mild Traumatic Brain Injury

Purpose: To test if the medication prazosin to see if it affects levels of tau and beta-amyloid in the brain of persons with mild TBI.

Mild Traumatic Brain Injury (TBI) From Explosions Is A Common Injury Of Veterans, And Multiple mild TBIs Can lead To Chronic Traumatic Encephalopathy (CTE) And Alzheimer's Disease Years Later. This Study Will Test The Approved Drug Prazosin In Veterans Who Have Experienced Mild TBIs To Explore Its Effects On Biomarkers Of These Diseases. 

RO7105705 for Moderate Alzheimer's Disease

Purpose: To evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of the investigational drug RO7105705 in older adults with moderate Alzheimer's disease.

This Phase II Trial Will Evaluate The Investigational Treatment RO7105705 For People With Moderate Alzheimer's Disease.

Riluzole for Mild Alzheimer's Disease

Purpose: To test the safety and effectiveness of the drug riluzole for treating mild Alzheimer's disease.

Riluzole, A Drug Used To Slow Down The Progress Of Amyotrophic Lateral Sclerosis (ALS), Will Be tested In People With Mild Alzheimer's Disease. Cognitive Functional Changes And Specific Imaging Biomarkers Will Be Evaluated.

Role of the Nicotinic System in Cognitive Aging

Purpose: To examine the role of a subset of receptors in the brain, called the nicotinic system, in memory and thinking and healthy aging.

This Phase I study Will Investigate The Role Of The Nicotinic System In The Brain, A Subset Of The Cholinergic System, On Memory And Thinking And Healthy Aging By Using Stimulants And Blockers To Examine Brain Activation Patterns.

S-Equol for Alzheimer's Disease

Purpose: To test the safety and tolerability of S-equol, a compound that acts like estrogen in the body, and its effects on cognition in adults with Alzheimer's disease.

S-equol Is A Compound That Acts Like Estrogen In The Body And Is Available As An Over-the-counter Supplement. In This Study, Researchers Will Test The Safety And Tolerability Of A Therapeutic Dose Of S-equol And Its Effects On Cognition In Adults With Alzheimer's Disease.

Safety and Efficacy of Gantenerumab for Early Alzheimer's

Purpose: To evaluate the safety and efficacy of the investigational drug gantenerumab in people with early Alzheimer's disease.

This Phase III Clinical Trial Will Evaluate The Safety And Efficacy Of Gantenerumab In People With Early-stage Alzheimer's Disease. This Trial Is Similar To Gantenerumab For Early Alzheimer's Disease, But Recruiting In Different Locations.

Salsalate for Mild to Moderate Alzheimer's Disease

Purpose: To test the safety and tolerability of twice daily salsalate in adults with mild to moderate Alzheimer's Disease.

The Purpose Of The Study Is To Test The Safety And Tolerability Of Twice Daily Salsalate, A Nonsteroidal Anti-inflammatory Drug (NSAID), In Adults With Mild To Moderate Alzheimer's Disease.

Stem Cell Infusion for Alzheimer's Disease

Purpose: To test the safety and efficacy of a stem-cell infusion to treat people with Alzheimer's disease.

This Phase I Trial Will Test The Safety And Efficacy Of An Infusion Of Longeveron Mesenchymal Stem Cells (LMSCs) To Treat people With Alzheimer's Disease. Mesenchymal Stem Cells Have Been Found To Counteract The Neuroinflammation That Contributes To The Progression Of Alzheimers Disease.

TRx0237 for Mild Alzheimer's

Purpose: To determine the safety and efficacy of the investigational treatment TRx0237 in older adults with early Alzheimer's disease.

This Phase II/III Study Will Test The Safety And Efficacy Of The Investigational Drug TRx0237, Also Known As LMTX, In Older Adults With Mild Alzheimer's Disease.

Telmisartan to Prevent Alzheimer's in African Americans

Purpose: To determine if the blood-pressure medication telmisartan might help prevent Alzheimer's disease in African Americans.

This Study Is Designed To Determine If Telmisartan (Micardis), An Approved Medication For High Blood Pressure, May Help Prevent Alzheimer's Disease In African Americans, A Group At Relatively High Risk For Developing Alzheimer's.

Testing RO7126209 for Alzheimer's Disease in Healthy Volunteers

Purpose: To investigate the safety, tolerability, and pharmacokinetics of the investigational drug RO7126209 in healthy volunteers.

This Phase I Trial Will Test The Safety, Tolerability, And Pharmacokinetics Of Increasing Doses Of The Investigational Drug RO7126209, Which Is Being Developed As A Potential Treatment For Alzheimer's Disease.

Treatment of Psychosis and Agitation in Alzheimer's Disease

Purpose: To test lithium as a treatment for psychosis and agitation in older adults with Alzheimer's disease.

This Phase II Clinical Trial Will Test Low-dose Lithium As A Treatment For Psychosis And Agitation In Older Adults With Alzheimer's Disease. Currently, There Is No Federally Approved Medication For The Treatment Of Psychosis Or Agitation In Alzheimer's. Safety, Side Effects, And Efficacy Will Be Evaluated.

VU319 in Healthy Adult Volunteers

Purpose: To study the pharmacokinetics and effects of VU319 in healthy adults.

This Phase I Trial Of The Experimental Drug VU319, Developed To Improve Cognitive Function In People With Alzheimers, Will Study Its Effects in Healthy Adults.

Valacyclovir for Mild Alzheimer's Disease

Purpose: To test the efficacy of the anti-viral drug valacyclovir in treating adults with mild Alzheimer's disease who also test positive for herpes simplex virus-1 (HSV-1) or HSV-2.

This Phase II Study Will Test The Efficacy Of The Anti-viral Drug Valacyclovir (Valtrex) In Treating Adults With Mild Alzheimer's Disease Who Also Test Positive For Herpes Simplex Virus-1 (HSV-1) Or HSV-2.